Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL940666 | 0.98 | MAPT (0.36) | MAPTTP53GLACYP1A2KMT2A | |
| SCHEMBL939298 | 0.98 | MAPT (0.36) | MAPTTP53GLACYP1A2KMT2A | |
| Choline SCHEMBL972000 | 0.91 | MAPT (0.35) | MAPTTP53GLACYP1A2KMT2A | |
| SCHEMBL971125 | 0.91 | MAPT (0.35) | MAPTTP53GLAKMT2AGAA | |
| Acetylcholine SCHEMBL970813 | 0.89 | TP53 (0.33) | MAPTTP53GLACYP1A2CASR | |
| SCHEMBL939859 | 0.84 | GAA (0.47) | MAPTTP53GLACYP1A2KMT2A | |
| Ammonia Solution, Strong SCHEMBL939852 | 0.83 | GAA (0.46) | MAPTTP53GLACYP1A2KMT2A | |
| SCHEMBL1576599 | 0.83 | MAPT (0.35) | MAPTTP53GLACYP1A2KMT2A | |
| SCHEMBL19034725 | 0.82 | MAPT (0.36) | MAPTTP53GLACYP1A2KMT2A | |
| SCHEMBL15244182 | 0.81 | GAA (0.42) | MAPTTP53GLAKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009263-A1 | SELECTED SALTS OF 3-(5,6-DIHYDRO-1,4,2-DIOXAZIN-3-YL)-N-[(4,6-DIMETHOXYPYRIMIDIN-2-YL)CARBAMOYL]PYRIDINE-2-SULFONAMIDE, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS HERBICIDES AND PLANT GROWTH REGULATORS | BAYER CROPSCIENCE AG (DE) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009263-A1 | SELECTED SALTS OF 3-(5,6-DIHYDRO-1,4,2-DIOXAZIN-3-YL)-N-[(4,6-DIMETHOXYPYRIMIDIN-2-YL)CARBAMOYL]PYRIDINE-2-SULFONAMIDE, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS HERBICIDES AND PLANT GROWTH REGULATORS | DDT, DYRK4, SLTM | MAPT 3826/4885TP53 3307/4885GLA 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.